Fig. 1
Therapeutic scenario for patients with advanced non-squamous ‘undruggable’ NSCLC (EGFR wild type, ALK and ROS1 non-rearranged, PD-L1 < 50%)
Fig. 1 | BMC Medicine
Therapeutic scenario for patients with advanced non-squamous ‘undruggable’ NSCLC (EGFR wild type, ALK and ROS1 non-rearranged, PD-L1 < 50%)